

SMC Patient and Public Involvement Group (PAPIG)

Each year, SMC receives an increasing number of submissions from disease-specific patient interest groups. During 2007, SMC received 35 submissions (including 2 joint submissions) in support of 28 medicines from 30 disease-specific patient interest groups.

Asthma UK Scotland
British Cardiac Patients Association
British Lung Foundation
Daisy Network
Diabetes UK Scotland
Epilepsy Scotland
Education for Health/Allergy UK
Glycogen Storage Disease UK
HIV Scotland
Hysterectomy Association
James Whale Fund
Kidney Cancer UK
Leukaemia Care
Lymphoma Association
Myeloma UK
Multiple Sclerosis Society

National Association for Colitis and Crohns Disease
National Osteoporosis Society
National Rheumatoid Arthritis Society
Pain Association Scotland
Pain Concern
Parkinsons Disease Society
Royal National Institute of Blind People (RNIB)/Macular Disease Society
Roy Castle Lung Foundation
Sickle Cell Society
Signpost Forth Valley
Society for Mucopolysaccharide Diseases
UK Association of Narcoleptics
United Kingdom Thalassaemia Society
Women's Health Concern

Work continues around increasing the user-friendliness of the public involvement section of the SMC website.

Fifty percent of these submissions accompanied new medicines that received an acceptance/acceptance with restriction decision from SMC. This brings the total number of submissions from patient interest groups since 2003 to 117.

Efforts to raise awareness of SMC and its public involvement opportunities have continued. Letters encouraging submissions from patient interest groups that have not yet put forward a submission are posted each month and all groups are offered the opportunity to subscribe to the monthly updates detailing SMC's forthcoming work schedule and completed assessments. Three groups took up our offer to attend an SMC meeting as an observer. Work continues around increasing the user-friendliness of the public involvement section of the SMC website.

PAPIG have written to each Community Health Care Partnership General Manager offering attendance by a member of PAPIG at any event where awareness of SMC's public involvement opportunities could be highlighted to

patient representative bodies including Public Partnership Fora. General Managers were offered the opportunity to send a member of staff to observe an SMC meeting in order that they could better inform patient representative bodies as to how SMC incorporates patient and public testimony into its decision-making processes. During 2007, two patient representative bodies took up this opportunity.

Three new Public Partners have been recruited, one starting in July and two scheduled to commence in February 2008.

Members of the Patient and Public Involvement Group (PAPIG) have provided input at conferences including the Annual Conference of the European Society for Clinical Pharmacy and NHS Lothian's Excellence in Prescribing Conference. One public partner has become a member of the Royal Pharmaceutical Society Public Liaison Group.

Wendy Nganasurian
on behalf of PAPIG

Membership of PAPIG

Mrs Wendy Nganasurian	Public Partner (Chair)
Mrs Barbara Black	Public Partner (to September 2007)
Mr Jim Eadie	ABPI Scotland, SMC Member (to December 2007)
Ms Angela Munday	SMC Member (to June 2007)
Ms Pat Murray	SMC Member (from July 2007)
Mrs Sheila Tunstall-James	Public Partner (from July 2007)
Mr Mike Wallace	ABPI, SMC Member